A pilot study on the effect of active parenteral nutrition in patients receiving postoperative adjuvant chemotherapy after gastric cancer surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007118

Enrollment

Registered

2022-03-25

Start date

2022-04-11

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Among the patients who underwent radical resection for gastric or colorectal cancer that met the selection and exclusion criteria, who were scheduled to receive capecitabine/oxaliplatin as post

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients aged 18 to 80 years who were diagnosed with stage II or III after surgery for gastric cancer or colorectal cancer 2) Among patients falling under 1), who are starting capecitabine/oxaliplatin combination therapy as postoperative adjuvant chemotherapy 3) After surgery, their weight has decreased by more than 5% compared to before surgery until study registration 4) For chemotherapy Patients with adequate activity (ECOG 0-2) 5) Patients with adequate bone marrow and organ function at the time of initiation of treatment 6) Patients who fully understand and voluntarily consent to the study

Exclusion criteria

Exclusion criteria: 1) Patients with other carcinomas within 5 years 2) Patients with chronic inflammatory diseases (Chronic obstructive pulmonary disease [COPD], chronic hepatitis, Chronic kidney disease [CKD], inflammatory bowel disease [IBD], Chron`s disease [CD], chronic pancreatitis) 3) Patients who have undergone bowel surgery in the past except for appendicectomy 4) Patients with a history of heart failure (EF<40%) 5) Patients with serious diseases such as lung or heart or uncontrolled active infection 6) When it is judged that the protocol cannot be complied with, such as non-cooperative or impossible to follow up 7) If you are pregnant or lactating

Design outcomes

Primary

Measure	Time frame
We compare the weight change of the experimental group and the control in Phase 1 and Phase 2.	—

Secondary

Measure	Time frame
Height, body mass, body composition, anticancer dose, anticancer administration period, albumin, interleukin-6, tumor necrosis factor-alpha, C-reactive protein, ferritin	—

Countries

Korea, Republic of

Contacts

Public ContactJUN HO JI

Samsung Changwon Medical Center

junofanclub@hanmail.net+82-55-233-5842

Outcome results